This lets us make two conclusions: First, we suggest that if the clinicopathological analysis of receptor status results in hormone receptor negative or HER2-positive breast cancer, the next step to determine the prognosis could be to conduct a further genetic analysis of the tumor and determine the level of GPC1 expression. This evidence concerns the gene ERBB2 and neoplasm.